Harbor Investment Advisory LLC Sells 187 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Harbor Investment Advisory LLC decreased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 23.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 615 shares of the medical instruments supplier’s stock after selling 187 shares during the period. Harbor Investment Advisory LLC’s holdings in LeMaitre Vascular were worth $57,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of LMAT. NBC Securities Inc. grew its holdings in shares of LeMaitre Vascular by 73.2% in the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 183 shares in the last quarter. USA Financial Formulas bought a new position in shares of LeMaitre Vascular in the 3rd quarter valued at about $60,000. GAMMA Investing LLC grew its holdings in shares of LeMaitre Vascular by 34.3% in the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock valued at $68,000 after acquiring an additional 188 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of LeMaitre Vascular in the 2nd quarter valued at about $82,000. Finally, Advisors Asset Management Inc. lifted its stake in LeMaitre Vascular by 180.2% in the 3rd quarter. Advisors Asset Management Inc. now owns 1,852 shares of the medical instruments supplier’s stock valued at $172,000 after purchasing an additional 1,191 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares of the company’s stock, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $98.00 on Thursday. LeMaitre Vascular, Inc. has a 52 week low of $56.04 and a 52 week high of $109.58. The firm has a market cap of $2.20 billion, a P/E ratio of 53.55, a price-to-earnings-growth ratio of 2.19 and a beta of 0.96. The firm’s 50-day simple moving average is $98.28 and its 200 day simple moving average is $92.19.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.33 EPS. As a group, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on LMAT. Oppenheimer restated an “outperform” rating and issued a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Cantor Fitzgerald started coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Barrington Research lifted their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Finally, StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.